Jason Davis
CIK: 0001443533
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- May 4, 2026FBLG
FibroBiologics, Inc.
Award(A)DirectStock Option (Right to Buy)
61.6K shares- - Mar 2, 2026FBLG
FibroBiologics, Inc.
Purchase(P)Direct70K shares at avg. $0.41$29K - Jun 9, 2025FBLG
FibroBiologics, Inc.
Award(A)DirectStock Option (Right to Buy)
450K shares-
1-3 of 3 transactions
About Davis Jason
Davis Jason (SEC CIK 0001443533) files insider reports with the SEC as Chief Financial Officer of FibroBiologics, Inc. (FBLG) and Chief Financial Officer of Virax Biolabs Group Ltd (VRAX).
Signal8 holds 5 ownership filings by Davis Jason (2 Form 3, 3 Form 4), filed between Jun 10, 2025 and May 4, 2026. Those filings report 3 transactions, from Jun 9, 2025 to May 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Davis Jason's filings is in HOUSTON,, TX.
Recent filings by Davis Jason
Other insiders filing for FibroBiologics, Inc. (FBLG)
- Khoja Hamid, Chief Scientific Officer
- Steinberg Leigh, Director
- Rubins Kathleen Hallisey, Director
- Hoffman Robert E., Director
- Cilento Richard C. Jr., Director
- Link Matthew, Director